Emerald Advisers LLC Grows Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Emerald Advisers LLC lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 146.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 371,711 shares of the company’s stock after acquiring an additional 220,804 shares during the quarter. Emerald Advisers LLC’s holdings in TransMedics Group were worth $23,176,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TMDX. Principal Financial Group Inc. lifted its stake in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares in the last quarter. State of Michigan Retirement System acquired a new position in TransMedics Group during the 4th quarter worth about $6,734,000. Public Sector Pension Investment Board acquired a new position in TransMedics Group during the 3rd quarter worth about $11,079,000. Raymond James Financial Inc. acquired a new position in TransMedics Group during the 4th quarter worth about $3,845,000. Finally, Vanguard Group Inc. lifted its stake in TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock worth $226,700,000 after acquiring an additional 40,860 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMDX. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Trading Up 0.3 %

NASDAQ:TMDX opened at $69.05 on Friday. The stock’s 50 day moving average price is $68.12 and its 200 day moving average price is $90.58. The company has a market capitalization of $2.32 billion, a PE ratio of 73.46 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.